drugset / Trial / NCT03254290

Color Stability of NeoMTA Pulpotomized Primary Teeth

NCT03254290

RandomizedSingle-groupSingle-blindTreatment

Summary

This randomized control study will use 15 pediatric subjects selected from the patient population in the pediatric dental clinic at Children's Medical Center Dental Clinic (CMC Dental Clinic). The study will use a within-subject control design whereby one tooth will be treated with a pulpotomy using the new formulation of MTA (NeoMTA Plus, Avalon Biomed Inc., Bradenton, FL, USA) and restored with a multi-surface composite, and the other tooth with a formocresol pulpotomy and restored with a multi-surface composite; thus, approximately 15 teeth will be treated for each treatment group. The specific treated tooth will be randomized as to which side will receive the MTA or formocresol using sealed, opaque envelopes. Approximately 15 subjects will be needed for the study in order to elicit any significant findings as demonstrated by a power analysis.

Timeline

Start
2017-10-01
Primary completion
2018-06-30
Completion
2018-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Formocresol Other / unclassified
Subject NeoMTA Unknown

Indications